

Protecting and improving the nation's health

# Leptospirosis Enhanced Surveillance Protocol

Pilot study to improve the surveillance of laboratory-confirmed cases of leptospirosis

December 2016

# About Public Health England

Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. We do this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health, and are a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner.

Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000

www.gov.uk/phe
Twitter: @PHE\_uk

Facebook: www.facebook.com/PublicHealthEngland

Prepared by: Ebere Okereke, Kate Halsby, Colin Brown, Roberto Vivancos For queries relating to this document, please contact: Kate Halsby, Emerging Infections and Zoonoses Section, National Infection Service PHE Colindale, 0208 327 7818 or zoonoses@phe.gov.uk

#### © Crown copyright 2016

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL or email psi@nationalarchives.gsi.gov.uk. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published December 2016

PHE publications gateway number: 2016510



# Contents

About Public Health England	2
Purpose of this document	4
Background	4
UK Epidemiology and current surveillance systems	5
Co-ordination of surveillance activities	6
Workload implications	6
Methods	7
Case definition	7
Data collection	7
SOP for health protection teams	8
Analysis and interpretation of data and dissemination of reports	9
Evaluation of the pilot	9
Annex	10

## Purpose of this document

This document sets out the protocol for the surveillance of **confirmed** cases of leptospirosis in England.

This surveillance is a pilot-enhanced surveillance system aimed at improving our understanding of leptospirosis in the UK to enable further development of guidance and policy.

The pilot has been proposed to run for **six months** and will be evaluated and decisions made for long-term surveillance.

#### 1.1 Background

Leptospirosis is a zoonotic disease caused by the spirochaete bacterium *Leptospira interrogans* of which only some strains are pathogenic. *L.* Icterohaemorrhagiae is the main serovar responsible for human disease. Leptospirosis is more common in tropical areas of the world, but also occurs throughout temperate areas and over one million infections are estimated to occur globally each year.

Humans mainly acquire infection by direct contact with the urine of chronically infected animals, particularly the brown rat *Rattus norvegicus*. Infection occurs when spirochaetes in urine, contaminated water or soil enter micro-abrasions in healthy intact skin, intact mucous membranes or conjunctiva. They may also cross the nasal mucosa and pass through the lungs (from inhalation of aerosolised animal body fluids). Individuals at increased risk include those working in the farming and water sports communities, with animal and water exposures. Person-to-person transmission is not known to occur.


Leptospirosis has changed over the years from being a predominantly occupational infection to one now more commonly associated with recreational activities. The risk of acquiring *Leptospira* infection is increased with exposure to inland surface waters both at home and abroad, especially involving water-based and adventure sports and where the risk of skin abrasions is high.

Occupational exposures still occur in those working with livestock or where there are exposures to rodents or their urine. In addition to sources such as livestock and wild rodents, cases have also been associated with pet rats.

#### 1.2 UK Epidemiology and current surveillance systems

As leptospirosis is not statutorily notifiable in England, Wales and Scotland, it is reportable as a laboratory isolate and surveillance is based on laboratory reports. In Northern Ireland, it is notifiable in humans under public health legislation. Our understanding of the epidemiology is incomplete due to the limited clinical and risk factor information provided on the reference laboratory request forms (see annex 1). In addition, laboratory diagnosis of leptospirosis is complex and requires multiple samples and clinical information to interpret the laboratory test results.

However, recent improvement in laboratory processes and partnership between the reference labs and the surveillance team has improved the identification of confirmed cases in real time. This therefore presents an opportunity to understand the epidemiology of leptospirosis in the country by undertaking enhanced surveillance.



#### 1.3 Objectives

The objectives of the leptospirosis surveillance system are to:

- understand the clinical and epidemiological characteristics of laboratory-confirmed cases of leptospirosis
- obtain information on risk factors to inform development of public health advice
- provide information to improve laboratory diagnostics

The objectives of the pilot study are:

- to determine the feasibility of collecting epidemiological information on laboratory-confirmed cases of leptospirosis
- to determine the work load involved with obtaining additional clinical and epidemiological information on confirmed cases of leptospirosis

#### 1.4 Co-ordination of surveillance activities

The Emerging Infections and Zoonoses section of the National Infection Service will lead the co-ordination of the surveillance system, including conducting epidemiological analysis and reports. Quarterly summary reports will be produced and disseminated through the quarterly zoonoses report in the Health Protection Report (HPR).

Health protection teams (HPTs) will have lead responsibility for obtaining surveillance activities information for confirmed cases and returning completed questionnaires to EIZ for analysis. The Field Epidemiology Service (FES) will assist by prompting and reminding HPTs to submit completed surveillance forms.

The laboratories that comprise the National Leptospirosis Service (Colindale and Porton) will be responsible for identifying confirmed cases and notifying the HPTs and EIZ.

#### 1.5 Workload implications

The average number of cases or leptospirosis reported each year in England is low, fewer than 80 cases/year, except in an outbreak. In 2015, 62 cases of leptospirosis, confirmed by the reference laboratories, were reported in England and Wales. The region with the most cases in 2015 was the South West (n=17). Thus the average number of cases per PHE centre is less than 10. See table 1 below.

Table 1: Confirmed leptospirosis cases by PHEC, Q1 -Q4, 2015

PHE centre	Q1	Q2	Q3	Q4	Total
East Midlands				3	3
East of England	1		3	3	7
London	1		5	4	10
North East		1			1
North West		1	1	5	7
South East	1	1	1	1	4
South West	5	2	4	6	17
Wales				2	2
West Midlands			1		1
Y&H		1	6	4	11
Total	8	6	21	28	63

However, it is recognised that there is often some delay between presentation and diagnosis, so patients may have been discharged before the diagnosis is confirmed and HPTs alerted. It will therefore be necessary to contact GPs or clinicians to obtain some epidemiological information. The pilot study will determine how challenging this might be to inform any longer-term surveillance plans.

### Methods

#### 2.1 Case definition

This surveillance is based only on **laboratory-confirmed** cases. The diagnostic methods on which this surveillance system will be based are immunological and genomic methods, as direct identification of leptospirosis is difficult.

A case of leptospirosis for surveillance will be confirmed by the PHE reference laboratories as follows:

#### Microscopic Agglutination Test (MAT): Confirmed case

- a single MAT titre of ≥ 320
- a rising MAT titre, rising to 320
- any four fold rise in MAT titre


#### **PCR: Confirmed case**

16S rRNA PCR positive on any sample

The final status of a case of leptospirosis as confirmed and therefore for inclusion in the surveillance system will be designated by a clinical microbiologist in the National Leptospirosis Service.

#### 2.2 Data collection

#### REF LAB → EIZ CIDSC & HPT (via e-lab) → EIZ CIDSC (FES act as local facilitator)



### 2.3 SOP for health protection teams

	Action	Responsible personnel	Comment
1	Diagnosis confirmed. Final case status assigned on lab system (MOLIS) (Selecting the final case status is required to trigger report sharing with HPT)	Duty clinical microbiologist, Colindale ref lab	
2	<ul> <li>lab report sent to HPT (based on postcode provided or source lab). Lab report will include weblink to enhanced surveillance questionnaire on select survey</li> <li>copy report sent to EIZ in Colindale</li> </ul>	MOLIS database manager (this will be automated)	Weblink will be to a select survey questionnaire, but the option to have a printable word document questionnaire is also available
3	Receiving HPT to forward e-lab report to appropriate HPT of residence for action	HPT (Information officer / Acute service desk)	HPT of source lab may not be HPT of case resident.
4	HPT to create a case record on HPZone (if not already on HPZone)	HPT	Case should be Leptospirosis confirmed. Unless species is indicated on e-lab report, select Lepstospira spp.
5	HPT to determine location and status of patient (still in hospital? Deceased?)	HPT	Contact hospital or GP
6	Complete enhanced surveillance questionnaire either directly with patient or next of kin	HPT	The questionnaire is designed for telephone or face-face administration by a professional, not for self-completion by patient
7	<ul> <li>upload copy of completed questionnaire to HPZone record.</li> <li>HPTs should consider setting a local HPZone action to remind them to return completed questionnaire</li> <li>submit questionnaire via select survey</li> <li>if the word document version is used, then email or fax completed questionnaire to EIZ within 2 weeks of notification of results</li> </ul>	HPT	Email address zoonoses@phe.gov.uk Secure fax no: 0208 905 9929
8	EIZ epi scientist to notify FES zoonoses lead of any outstanding questionnaires, every 4 weeks	EIZ	4 weeks after the result sent to e-lab.
9	FES to prompt HPTs to ensure questionnaire completed and returned	FES	
10	Completed enhanced surveillance questionnaires uploaded into leptospirosis database	EIZ	Any links indicating possible clusters / outbreaks identified will be notified to HPTs
11	Quarterly analysis report produced and disseminated	EIZ	Via HPR and through Centre & FES zoonoses leads
12	Final analysis and evaluation of pilot enhanced surveillance reported and shared	EIZ / FES	

#### 2.4 Analysis and interpretation of data and dissemination of reports

EIZ will be responsible for providing analysis of the datae and will flag up any changes in epidemiology identified from the surveillance system.

The analysis will be reported through the quarterly zoonoses report disseminated through the weekly HPR. The analysis will include:

- number of confirmed cases of leptospirosis in England and Wales by sex, age group and PHE centre of residence
- clinical presentation and outcome
- exposures / risk factors

#### 2.5 Evaluation of the pilot

The pilot-enhanced surveillance system will run for six months. At the end of this period, the surveillance system will be evaluated to determine the value to improved understanding of the epidemiology of leptospirosis in England and Wales and the workload implications of the process. A recommendation will then be made about long-term options for leptospirosis surveillance.

# Annex

### Annex 1: Leptospirosis laboratory request form

203	Leptosp Rare and Imported	Leptospirosis Request are and Imported Pathogens Laboratory			
Public Health England Please write clearly In dark ink	PHE Microbiology Se Porton Down, Salisbur Wiltshire SP4 DIG		Phone +4	4 (0)1980 612348 (9am - 5pm) 4 (0)1980 612100 (oncas) @phe.gov.uk uk/phe	PHE DX 6930400 Salisbury 92 SP
SENDER'S INFORMATIO	N	100000000000000000000000000000000000000		5.50.50.000	Control of the last
Sender's name and address			Report to	be sent FAO	
			Direct Ph	one	
			Direct Ph	ione fout of hours)	
			Purchase	order number	
			Project co	ode	
Postcode					
PATIENT/SOURCE INFO		No. of the last			TO SHOW THE REAL PROPERTY.
Human Animal* 0			Pense spec		
Inpatient Outpatient	GP Patient 0	ther*	*Ficase spec	Ny .	
NHS number			Gender	male femal	e
Surriame			Date of b	irth	Age
Forename			Patient's p	oostcode	
rurename			Patient's F	HPT	
Hospital number			Ward	ITU Dialysis Other ward	/clinic
Hospital name // different from ser	nder's name)		Pregnant	Yes No Unkn	own .
Have previous samples been s		es 🔲 No	RIPL Lab re	ef. no P1 _ CO	
SAMPLE INFORMATION Sample type	Your reference	-			I amortinami II
CSF Urine (only send with paire Blood Culture Other glease specify) Date of collection Date sent to RIP.	ed sera)	Time	Note: if information	road the Infectious Diseases, nould call the Imported Fever 0844 77 8 ection with a Hazard Group 4 path i or travel history, you must contact the box If your clinical sample	Service on 8 990 ogen is suspected from cli t this number before send
RIPL will select the mo	ost appropriate Le eased on informat ravel and clinical	ion	within 7 d	osis PCR will be performed on a lays post onset and on all urine MANTAVIRUS TESTS	
Refer to our user man	ual for further det GICAL INFORMATION	ON			-
Refer to our user man CLINICAL/EPIDEMIOLO Foreign Travel within previous	ual for further det GICAL INFORMATION	Asymptomat		Other clinical details	-
Refer to our user man CUNICAL/EPIDEMIOLO Foreign Travel within previous Purpose of travel	ual for further det GICAL INFORMATION	Asymptomat  Fever			
Refer to our user mani CLINICAL/EPIDEMIOLOG Foreign Travel within previous Purpose of travel Date of travel from usp	ual for further det GICAL INFORMATION	Asymptomat Sever Headache	ic		
Refer to our user mani CLINICAL/EPIDEMIOLO Foreign Travel within previous Purpose of travel Date of travel from use 1 Date returned from use 1	ual for further det GICAL INFORMATION	Asymptomat  Fever	ic		
Refer to our user many CLINICAL/EPIDEMIOLO Foreign Travel within previous Purpose of travel Date of travel from use   1 Date returned flours   1 Onset date   1	ual for further det GICAL INFORMATION	Asymptomat     fever     Headache     Flu-like Illness	ic		
Refer to our user mani CLINICAL/EPIDEMIOLO Foreign Travel within previous Purpose of travel Date of travel from use 1 Date returned from use 1	ual for further del GICAL INFORMATIO s 21days? Yes No	ON Asymptomat Fever Headache Flu-like Illness Myalgia	ic		
Refer to our user many CLINICAL/EPIDEMIOLO Foreign Travel within previous Purpose of travel Date of travel from use   1 Date returned flours   1 Onset date   1	ual for further del GICAL INFORMATIO s 21days? Yes No  Urban area Rural area	Asymptomat	ic		
Refer to our user many CLINICAL/EPIDEMIOLO Foreign Travel within previous Purpose of travel Date of travel from use   1 Date returned flours   1 Onset date   1	ual for further del GICAL INFORMATIO s 21days? Yes No  Urban area Rural area Open country	Asymptomat Asymptomat Fever Headache Flu-like illness Myalgia Malaise Diarrhoea Vomiting Abnormal live	ic er function		
Refer to our user many CLINICAL/EPIDEMIOLO Foreign Travel within previous Purpose of travel Date of travel from use   1 Date returned flours   1 Onset date   1	ual for further del GICAL INFORMATIO s 21days? Yes No  Urban area Rural area Open country Forests	Asymptomat Asymptomat Fever Headache Flu-like illness Myalgia Malaise Diarrhoea Vomiting Abnormal live	ic er function		
Refer to our user mani CLINICAL/EPIDEMIOLOG Foreign Travel within previous Purpose of travel Date of travel from use 1 Date returned from use 1 Onset date 1 Countries/areas visited	ual for further del GICAL INFORMATIO s 21days? Yes No  Urban area Rural area Open country Forests	Asymptomat Asymptomat Fever Headache Flu-like illness Myalgia Malaise Diarrhoea Vomiting Abnormal live Hepatic failur	ic or function e		
Refer to our user manicular control of the control	ual for further del GICAL INFORMATIC s 21days? Yes No  Urban area Rural area Open country Forests contact*	Asymptomat Asymptomat Fever Headache Flu-like illness Myalgia Malaise Diarrhoea Vomiting Abnormal live Hepatic failur Jaundice Abnormal ren Renal replace	er function e al function ment	Other clinical details	
Refer to our user manicular control of travel within previous Purpose of travel  Date of travel from use 1  Onset date 1  Countries/areas visited  Water contact* Animal *Prease specify	ual for further del GICAL INFORMATIC s 21days? Yes No  Urban area Rural area Open country Forests contact*	Asymptomat	er function e al function ment red		
Refer to our user manicular control of travel within previous Purpose of travel  Date of travel from use 1  Date returned from 1  Onset date 1  Countries/areas visited  Water contact* Animal  *Rease specify	ual for further del GICAL INFORMATIC s 21days? Yes No  Urban area Rural area Open country Forests contact*	Asymptomat Asymptomat Fever Headache Flu-like illness Myalgia Malaise Diarrhoea Vomiting Abnormal live Hepatic failur Jaundice Abnormal ren Renal replace	er function e al function ment red	Other clinical details	

#### Annex 2

# Public Health England

#### PILOT LEPTOSPIROSIS EPIDEMIOLOGICAL SURVEILLANCE

PHE Emerging Infections and Zoonoses Section, National Infection Service

61 Colindale Avenue, London NW9 5EQ.

Tel: 020 8327 7818 Secure Fax: 020 8905 9929

Email: zoonoses@phe.gov.uk

Patient Details			
SURNAME:	FOI	RENAME:	
<b>D.O.B.:</b> (DD/MM/YYYY):/		NDER: MALE	☐ FEMALE
IS NUMBER: POSTCODE OF RESIDENCE			ENCE
HPZONE NO:	РН	E CENTRE:	
PART A: Clinical presentati	ion		
1) Onset date: (DD/MM/YYY	Y):/		
2) Date of first presentation	(if onset date unknow	wn DD/MM/YYYY): _	/
3) Hospitalised?	es $\square$	No	Unknown
4) Was the clinical presentation	tion severe?	Yes	□ No
(Severe includes: admission to therapy, hepatic failure, menin			, renal dialysis or other renal replacement organ failure, shock)
5) Did the patient have pre-e	existing on-going imr	mune-suppression	of any cause?  Yes  No
			Unknown
Please comment:			
PART B: Outcome			
6) What was the outcome?			
Recovered	Still Hospitalised / I	Recovering	☐ Died ☐ Unknown
☐ Prolonged clinical complic	ations. Comment:		
PART C: Travel History			
7) Has the patient recently to	ravelled <u>WITHIN</u> the l	UK, (returning in the	e last 30 days before onset)?
☐ Yes ☐ No	☐ Unknown If ye	es, please provide	the following details:
Country visited	,	D/MM/YYYY)	Comment
	From	То	
8) Has the patient recently to	ravelled <u>OUTSIDE</u> the	e UK (returning in t	he last 30 days before onset)?
☐ Yes ☐ No	Unknown If ye	es, please provide t	the following details:
COUNTRY visited	Dates (DD	D/MM/YYYY)	Comment
	From	То	
	_		

PART D: Risk activities / exposures			
9) At the time of onset, did the patient participate i Leptospirosis?	n any of the fo	llowing ac	tivities associated with ri
Occupational exposure:			
Occupation	In the UK	Abroad	Comment / Detail
Working in rivers / floodwater or other surface water			
Sewage worker			
Refuse collection			
Park worker			
Pest control			
Agricultural worker			
Abattoir worker			
Veterinary staff			
Laboratory worker			
Pet shop worker			
Other			
Animal contact: Animal	In the UK	Abroad	Comment / Detail
Dog			
Cat			
Pet rodent			
Wild rodent			
Cattle			
Other			
Water activities (fresh / surface water, not including			
Activity / exposure	In the UK	Abroad	Comment / Detail
Swimming in treated water (eg indoor / outdoor pool)			
Swimming in untreated water (eg rivers, streams etc)			
Canoeing			
Fishing			
Potholing / Caving			
Mading in aurface water			
wading in Surface water		1	1
Wading in surface water  White water rafting  Triathlon / Iron man			

PART E: Please provide any further comment					
Date completed:/					
Completed by:	Contact phone no:				
HPT:	PHE Centre:				

Thank you for your time and assistance.